Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$229
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
CJC-1295 No DAC is a growth-hormone-axis research peptide.
Research panels in this class typically compare GHRHR versus GHSR-1a pathway contributions, examine how DAC versus non-DAC half-life extension changes receptor-occupancy kinetics, or profile selectivity differences between ipamorelin and non-selective secretagogues. The GH fragment AOD-9604 (residues 176–191 of the GH sequence) is separately relevant as a lipolytic fragment that activates β3-adrenergic receptor signalling in adipocyte assays without engaging the somatotropic axis or IGF-1R.
Browse Inventory
In research literature, CJC-1295 No DAC is generally treated as a growth-hormone-axis research peptide. Peptides in the GH-axis research class act primarily at two receptor targets: the growth-hormone-releasing hormone receptor (GHRHR), a class B GPCR that couples Gs to cAMP/PKA and GH gene transcription in somatotroph cell models; or the ghrelin/GH secretagogue receptor (GHSR-1a), a constitutively active class A GPCR whose agonism also triggers Gq-IP3 calcium flux in addition to Gs signalling. GHRH analogs (sermorelin, tesamorelin, CJC-1295) target GHRHR; ghrelin mimetics (GHRP-2, GHRP-6, ipamorelin) target GHSR-1a. CJC-1295 with DAC uses a reactive maleimide group to form a covalent thioether bond with albumin Cys34, extending half-life to days — an unusual mechanism studied in covalent protein-binding and pharmacokinetic assays. Ipamorelin is notable for GHSR-1a selectivity with minimal off-target ACTH or cortisol pathway stimulation in pituitary cell assays, distinguishing it from less selective GHRP-6.
Research panels in this class typically compare GHRHR versus GHSR-1a pathway contributions, examine how DAC versus non-DAC half-life extension changes receptor-occupancy kinetics, or profile selectivity differences between ipamorelin and non-selective secretagogues. The GH fragment AOD-9604 (residues 176–191 of the GH sequence) is separately relevant as a lipolytic fragment that activates β3-adrenergic receptor signalling in adipocyte assays without engaging the somatotropic axis or IGF-1R. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether CJC-1295 No DAC behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for CJC-1295 No DAC should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for CJC-1295 No DAC is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare CJC-1295 No DAC with CJC (NO DAC) + IPA, CJC-1295 DAC, and PT-141, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 2 labelled variants: 5mg and 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
CJC-1295 No DAC is generally discussed as a growth-hormone-axis research peptide. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
